This comprehensive review discusses the dosing strategies of cancer treatment drugs for
patients with impaired kidney function, specifically those with chronic kidney disease (CKD) …

Patients with malignancies have a high prevalence of kidney disease and are often treated
with antineoplastic agents that undergo kidney metabolism or excretion or clearance via …

Anticancer drug therapy for cancer is developing rapidly, including molecular-targeted drugs
and immune checkpoint inhibitors that are used in clinical settings in addition to …

Conventional chemotherapies remain the mainstay of treatment for many malignancies.
Kidney complications of these therapies are not infrequent and may have serious …

Chemotherapeutic agents used to treat cancer generally have narrow therapeutic indices
along with potentially serious adverse toxicities. Many cancer drugs are at least partially …

Advances in cancer drug therapy have led to improvements in the outcomes of cancer
patients, as well as increasing numbers of patients undergoing anticancer chemotherapy …

Chronic kidney disease (CKD) is one of the most disabling disorders with significant
comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are …

The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …

Cisplatin should be administered with diuretics and Magnesium supplementation under
adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR …

Renal insufficiency has been shown to be highly prevalent in patients with cancer. This renal
insufficiency has been reported to be associated with reduced overall survival and …